Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03987308 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 2, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: details revised at 1 of 29 entriesv3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 10 more changesShow less
    • Enrollment target: 260 to 115
    • Primary completion date: Jun 30, 2021 to Sep 2025
    • Primary endpoint revised
    • Study sites: 9 to 16
    • Study completion date: Dec 30, 2021 to Dec 2025
    • Start date changed from estimate of Jul 1, 2019 to Jul 2, 2019
    • Eligibility criteria shortened, about 175 words
    • Secondary endpoints: 24 to 29
    • Study title shortened, about 7 words
    • Study description shortened, about 1 word
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Beijing Hospital
20 trials monitored
See 2 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Type 2 Diabetes
2,231 trials monitored
See 111 trials at risk
The efficacy, safety and post-treatment disease control will be compared between groups of continuous subcutaneous Beinaglutide infusion and continuous subcutaneous insulin infusion (CSII) in adult patients with newly diagnosed type 2 diabetes.
Trial Details
NCT Number NCT03987308
Lead Sponsor Beijing Hospital
Conditions
(from sponsor)		 Type 2 Diabetic Patients, T2DM (Type 2 Diabetes Mellitus), T2DM
Related terms Diabetes Mellitus, Type 2
Enrollment 115 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov